Cargando…

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis

Experimental autoimmune encephalomyelitis (EAE) is a relevant animal model of multiple sclerosis (MS). Oxidative stress and chronic inflammation play a major role in the pathogenesis of MS and EAE. Melatonin, a neurohormone, has potent anti-inflammatory properties. The aim of our study was to assess...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ortíz, Genaro Gabriel, Briones-Torres, Ana Laura, Benitez-King, Gloria, González-Ortíz, Luis Javier, Palacios-Magaña, Claudia Verónica, Pacheco-Moisés, Fermín Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268121/ https://www.ncbi.nlm.nih.gov/pubmed/35807462 http://dx.doi.org/10.3390/molecules27134217

Ejemplares similares

Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis
por: Koc, Ümmügülsüm, et al.
Publicado: (2023)

Cellular and Biochemical Actions of Melatonin which Protect Against Free Radicals: Role in Neurodegenerative Disorders
por: Ortiz, Genaro G, et al.
Publicado: (2008)

Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)

Immunomodulatory therapy with glatiramer acetate reduces endoplasmic reticulum stress and mitochondrial dysfunction in experimental autoimmune encephalomyelitis
por: Makar, Tapas K., et al.
Publicado: (2023)

Glatiramer acetate treatment negatively regulates type I interferon signaling
Publicado: (2015)

Glatiramer acetate treatment negatively regulates type I interferon signaling
por: Molnarfi, Nicolas, et al.
Publicado: (2015)

Synthetic Cationic Autoantigen Mimics Glatiramer Acetate Persistence at the Site of Injection and Is Efficacious Against Experimental Autoimmune Encephalomyelitis
por: Song, Jimmy Y., et al.
Publicado: (2021)

Treatment of Chronic Experimental Autoimmune Encephalomyelitis with Epigallocatechin-3-Gallate and Glatiramer Acetate Alters Expression of Heme-Oxygenase-1
por: Janssen, Antonia, et al.
Publicado: (2015)

Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis
por: Green, Laura K, et al.
Publicado: (2017)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

Process signatures in glatiramer acetate synthesis: structural and functional relationships
por: Campos-García, Víctor R., et al.
Publicado: (2017)

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2021)

Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone(®)
por: Lipsky, Peter, et al.
Publicado: (2021)

Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
por: Neuhaus, Oliver, et al.
Publicado: (2021)

Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon
por: Fernández-Fournier, Mireya, et al.
Publicado: (2015)

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura
por: Sagy, Iftach, et al.
Publicado: (2016)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
por: Komlosh, Arthur, et al.
Publicado: (2019)

Bullous pemphigoid as an injection site reaction of glatiramer acetate
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2019)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
por: Kasindi, Arielle, et al.
Publicado: (2022)

An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate
por: Erzina, Dina, et al.
Publicado: (2021)

Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson's Disease
por: Jiménez-Delgado, Alicia, et al.
Publicado: (2021)

Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate
por: Rojas-Morales, Emmanuel, et al.
Publicado: (2019)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population
por: Kapica-Topczewska, Katarzyna, et al.
Publicado: (2019)

CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease
por: Tyler, Andrew F., et al.
Publicado: (2013)

Melatonin: A Neurotrophic Factor?
por: Miranda-Riestra, Armida, et al.
Publicado: (2022)

Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
por: de Oliveira, Tatiana de Melo Gomes, et al.
Publicado: (2008)

Glatiramer acetate desensitisation in multiple sclerosis patients - the case report
por: Novotna, Bronislava, et al.
Publicado: (2014)

Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
por: Izquierdo, Guillermo, et al.
Publicado: (2015)

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial
por: Arnold, Douglas L., et al.
Publicado: (2013)

Metabolic response to glatiramer acetate therapy in multiple sclerosis patients
por: De Riccardis, Lidia, et al.
Publicado: (2016)

Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
por: D’Alessandro, Josephine, et al.
Publicado: (2017)

Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate
por: Vlahova, Lyubomira, et al.
Publicado: (2021)

Flare Up Reaction During Provocation Test to Glatiramer Acetate in a Patient With Allergy to Interferon Beta1a
por: Minciullo, Paola L., et al.
Publicado: (2014)

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
por: Sánchez-de la Rosa, Rainel, et al.
Publicado: (2015)

Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients
por: Lee, Andrew, et al.
Publicado: (2017)

Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis
por: Peterka, Marek, et al.
Publicado: (2023)

Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
por: Bergvall, Niklas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_elk91achfhbimn4u2t8t3psne6